Low Serum Fibroblast Growth Factor 21 Level and Its Altered Regulation by Thyroid Hormones in Patients with Hashimoto’s Thyroiditis on Levothyroxine Substitution

Background/Objectives: Fibroblast growth factor 21 (FGF21) is a hormonal regulator of lipid and glucose metabolism exerting protection against atherosclerosis by multiple actions on the blood vessels, liver, and adipose tissues. We aimed to investigate serum FGF21 level and its relation to thyroid h...

Full description

Saved in:
Bibliographic Details
Published inMetabolites Vol. 14; no. 10; p. 565
Main Authors Berta, Eszter, Halmi, Sándor, Molnár, István, Hutkai, Dávid, Csiha, Sára, Bhattoa, Harjit Pal, Lőrincz, Hajnalka, Somodi, Sándor, Katkó, Mónika, Harangi, Mariann, Paragh, György, Nagy, Endre V., Bodor, Miklós
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 01.10.2024
MDPI
Subjects
Online AccessGet full text
ISSN2218-1989
2218-1989
DOI10.3390/metabo14100565

Cover

Abstract Background/Objectives: Fibroblast growth factor 21 (FGF21) is a hormonal regulator of lipid and glucose metabolism exerting protection against atherosclerosis by multiple actions on the blood vessels, liver, and adipose tissues. We aimed to investigate serum FGF21 level and its relation to thyroid hormones and metabolic parameters among patients with Hashimoto’s thyroiditis (HT). Methods: Eighty patients with HT on levothyroxine treatment and eighty-two age- and BMI-matched adults without thyroid disease serving as controls were enrolled. Serum FGF21 concentrations were determined with an enzyme-linked immunosorbent assay. Results: Median serum FGF21 level was significantly lower in HT patients compared with controls (74.2 (33.4–148.3) pg/mL vs. 131.9 (44.8–236.3) pg/mL; p = 0.03). We found a positive correlation between FGF21 and age, triglyceride, total cholesterol, and low-density lipoprotein cholesterol in both groups, while thyroid stimulating hormone and C-reactive protein showed a positive correlation, and thyroxine had an inverse correlation with FGF21 only in control subjects. According to multiple regression analyses, thyroid status is the main predictor of FGF21 in healthy controls, while it is not a significant predictor of FGF21 among HT patients on levothyroxine supplementation therapy. Conclusions: Our results indicate that the physiological role of thyroid function in the regulation of FGF21 synthesis is impaired in HT patients, which may contribute to the metabolic alterations characteristic of HT patients.
AbstractList Fibroblast growth factor 21 (FGF21) is a hormonal regulator of lipid and glucose metabolism exerting protection against atherosclerosis by multiple actions on the blood vessels, liver, and adipose tissues. We aimed to investigate serum FGF21 level and its relation to thyroid hormones and metabolic parameters among patients with Hashimoto's thyroiditis (HT). Eighty patients with HT on levothyroxine treatment and eighty-two age- and BMI-matched adults without thyroid disease serving as controls were enrolled. Serum FGF21 concentrations were determined with an enzyme-linked immunosorbent assay. Median serum FGF21 level was significantly lower in HT patients compared with controls (74.2 (33.4-148.3) pg/mL vs. 131.9 (44.8-236.3) pg/mL; = 0.03). We found a positive correlation between FGF21 and age, triglyceride, total cholesterol, and low-density lipoprotein cholesterol in both groups, while thyroid stimulating hormone and C-reactive protein showed a positive correlation, and thyroxine had an inverse correlation with FGF21 only in control subjects. According to multiple regression analyses, thyroid status is the main predictor of FGF21 in healthy controls, while it is not a significant predictor of FGF21 among HT patients on levothyroxine supplementation therapy. Our results indicate that the physiological role of thyroid function in the regulation of FGF21 synthesis is impaired in HT patients, which may contribute to the metabolic alterations characteristic of HT patients.
Fibroblast growth factor 21 (FGF21) is a hormonal regulator of lipid and glucose metabolism exerting protection against atherosclerosis by multiple actions on the blood vessels, liver, and adipose tissues. We aimed to investigate serum FGF21 level and its relation to thyroid hormones and metabolic parameters among patients with Hashimoto's thyroiditis (HT).BACKGROUND/OBJECTIVESFibroblast growth factor 21 (FGF21) is a hormonal regulator of lipid and glucose metabolism exerting protection against atherosclerosis by multiple actions on the blood vessels, liver, and adipose tissues. We aimed to investigate serum FGF21 level and its relation to thyroid hormones and metabolic parameters among patients with Hashimoto's thyroiditis (HT).Eighty patients with HT on levothyroxine treatment and eighty-two age- and BMI-matched adults without thyroid disease serving as controls were enrolled. Serum FGF21 concentrations were determined with an enzyme-linked immunosorbent assay.METHODSEighty patients with HT on levothyroxine treatment and eighty-two age- and BMI-matched adults without thyroid disease serving as controls were enrolled. Serum FGF21 concentrations were determined with an enzyme-linked immunosorbent assay.Median serum FGF21 level was significantly lower in HT patients compared with controls (74.2 (33.4-148.3) pg/mL vs. 131.9 (44.8-236.3) pg/mL; p = 0.03). We found a positive correlation between FGF21 and age, triglyceride, total cholesterol, and low-density lipoprotein cholesterol in both groups, while thyroid stimulating hormone and C-reactive protein showed a positive correlation, and thyroxine had an inverse correlation with FGF21 only in control subjects. According to multiple regression analyses, thyroid status is the main predictor of FGF21 in healthy controls, while it is not a significant predictor of FGF21 among HT patients on levothyroxine supplementation therapy.RESULTSMedian serum FGF21 level was significantly lower in HT patients compared with controls (74.2 (33.4-148.3) pg/mL vs. 131.9 (44.8-236.3) pg/mL; p = 0.03). We found a positive correlation between FGF21 and age, triglyceride, total cholesterol, and low-density lipoprotein cholesterol in both groups, while thyroid stimulating hormone and C-reactive protein showed a positive correlation, and thyroxine had an inverse correlation with FGF21 only in control subjects. According to multiple regression analyses, thyroid status is the main predictor of FGF21 in healthy controls, while it is not a significant predictor of FGF21 among HT patients on levothyroxine supplementation therapy.Our results indicate that the physiological role of thyroid function in the regulation of FGF21 synthesis is impaired in HT patients, which may contribute to the metabolic alterations characteristic of HT patients.CONCLUSIONSOur results indicate that the physiological role of thyroid function in the regulation of FGF21 synthesis is impaired in HT patients, which may contribute to the metabolic alterations characteristic of HT patients.
Background/Objectives: Fibroblast growth factor 21 (FGF21) is a hormonal regulator of lipid and glucose metabolism exerting protection against atherosclerosis by multiple actions on the blood vessels, liver, and adipose tissues. We aimed to investigate serum FGF21 level and its relation to thyroid hormones and metabolic parameters among patients with Hashimoto’s thyroiditis (HT). Methods: Eighty patients with HT on levothyroxine treatment and eighty-two age- and BMI-matched adults without thyroid disease serving as controls were enrolled. Serum FGF21 concentrations were determined with an enzyme-linked immunosorbent assay. Results: Median serum FGF21 level was significantly lower in HT patients compared with controls (74.2 (33.4–148.3) pg/mL vs. 131.9 (44.8–236.3) pg/mL; p = 0.03). We found a positive correlation between FGF21 and age, triglyceride, total cholesterol, and low-density lipoprotein cholesterol in both groups, while thyroid stimulating hormone and C-reactive protein showed a positive correlation, and thyroxine had an inverse correlation with FGF21 only in control subjects. According to multiple regression analyses, thyroid status is the main predictor of FGF21 in healthy controls, while it is not a significant predictor of FGF21 among HT patients on levothyroxine supplementation therapy. Conclusions: Our results indicate that the physiological role of thyroid function in the regulation of FGF21 synthesis is impaired in HT patients, which may contribute to the metabolic alterations characteristic of HT patients.
Audience Academic
Author Csiha, Sára
Lőrincz, Hajnalka
Somodi, Sándor
Bodor, Miklós
Halmi, Sándor
Bhattoa, Harjit Pal
Harangi, Mariann
Hutkai, Dávid
Nagy, Endre V.
Berta, Eszter
Paragh, György
Molnár, István
Katkó, Mónika
AuthorAffiliation 6 Kálmán Laki Doctoral School, University of Debrecen, H-4032 Debrecen, Hungary
1 Division of Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary; lorincz_hajnalka@belklinika.com (H.L.); somodi@med.unideb.hu (S.S.); harangi.mariann@med.unideb.hu (M.H.); paragh.gyorgy@med.unideb.hu (G.P.)
4 Division of Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary; katko.monika@med.unideb.hu (M.K.); endrenagy@med.unideb.hu (E.V.N.)
2 Department of Clinical Basics, Faculty of Pharmacy, University of Debrecen, H-4032 Debrecen, Hungary; csiha.sara@med.unideb.hu (S.C.); bodor.miklos@med.unideb.hu (M.B.)
5 Division of Nephrology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary; hutkai.david@med.unideb.hu
3 Doctoral School of Health Sciences, University of Debrecen, H-4032 Debrecen, Hungary; halmi.sandor@med.unideb.hu (S.H.); d
AuthorAffiliation_xml – name: 8 Department of Emergency Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary
– name: 4 Division of Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary; katko.monika@med.unideb.hu (M.K.); endrenagy@med.unideb.hu (E.V.N.)
– name: 6 Kálmán Laki Doctoral School, University of Debrecen, H-4032 Debrecen, Hungary
– name: 2 Department of Clinical Basics, Faculty of Pharmacy, University of Debrecen, H-4032 Debrecen, Hungary; csiha.sara@med.unideb.hu (S.C.); bodor.miklos@med.unideb.hu (M.B.)
– name: 3 Doctoral School of Health Sciences, University of Debrecen, H-4032 Debrecen, Hungary; halmi.sandor@med.unideb.hu (S.H.); dr.molnar.istvan@med.unideb.hu (I.M.)
– name: 7 Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary; harjit@med.unideb.hu
– name: 5 Division of Nephrology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary; hutkai.david@med.unideb.hu
– name: 1 Division of Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary; lorincz_hajnalka@belklinika.com (H.L.); somodi@med.unideb.hu (S.S.); harangi.mariann@med.unideb.hu (M.H.); paragh.gyorgy@med.unideb.hu (G.P.)
Author_xml – sequence: 1
  givenname: Eszter
  orcidid: 0000-0003-0439-9867
  surname: Berta
  fullname: Berta, Eszter
– sequence: 2
  givenname: Sándor
  surname: Halmi
  fullname: Halmi, Sándor
– sequence: 3
  givenname: István
  surname: Molnár
  fullname: Molnár, István
– sequence: 4
  givenname: Dávid
  surname: Hutkai
  fullname: Hutkai, Dávid
– sequence: 5
  givenname: Sára
  surname: Csiha
  fullname: Csiha, Sára
– sequence: 6
  givenname: Harjit Pal
  orcidid: 0000-0002-4909-0065
  surname: Bhattoa
  fullname: Bhattoa, Harjit Pal
– sequence: 7
  givenname: Hajnalka
  orcidid: 0009-0000-5303-3082
  surname: Lőrincz
  fullname: Lőrincz, Hajnalka
– sequence: 8
  givenname: Sándor
  surname: Somodi
  fullname: Somodi, Sándor
– sequence: 9
  givenname: Mónika
  orcidid: 0000-0002-9791-9288
  surname: Katkó
  fullname: Katkó, Mónika
– sequence: 10
  givenname: Mariann
  orcidid: 0000-0001-9761-9595
  surname: Harangi
  fullname: Harangi, Mariann
– sequence: 11
  givenname: György
  surname: Paragh
  fullname: Paragh, György
– sequence: 12
  givenname: Endre V.
  orcidid: 0000-0002-9286-6471
  surname: Nagy
  fullname: Nagy, Endre V.
– sequence: 13
  givenname: Miklós
  surname: Bodor
  fullname: Bodor, Miklós
BackLink https://www.ncbi.nlm.nih.gov/pubmed/39452947$$D View this record in MEDLINE/PubMed
BookMark eNqFkstuEzEUhkeoiJbSLUtkiQ2btLZnxp5ZoapqmkiRQLSsLdtzJnE0Ywfb05Adr8GaN-NJcJregpCwF7aO__P53F5nB9ZZyLK3BJ_meY3PeohSOVIQjEtWvsiOKCXViNRVffDsfpidhLDEaTFcckxeZYd5XZS0LvhR9mvm1uga_NCjsVHeqU6GiK68W8cFGksdnUeUoBncQoekbdA0BnTeRfDQoC8wHzoZjbNIbdDNYuOdadDE-T7FGZCx6HN6BZtc1ibxJjIsTO-i-_3jZ3jQm2gCSoT0hYtb03djAV0PKkQThy38TfaylV2Ak_vzOPs6vry5mIxmn66mF-ezkS4xj6OaaVxAq2gu21oTWVHATOaFqmihS8IU1rhSlLU1pxRzxYmWikuuMVayaar8OJvuuI2TS7Hyppd-I5w04s7g_FxIH43uQFSgFTRc16ViBbBcKlxDxTHmoLDUNLHOdqzBruRmLbvuEUiw2HZP7HcveXzceawG1UOjU9m87PbC2H-xZiHm7lYQUuLUT5YIH-4J3n0bIETRm6Ch66QFNwSRE5pGALN8G977v6RLN3ibqnun4kXBOH9SzWXK2djWpY_1FirOK1IUmDCKk-r0H6q0G-iNTpPQmmTfc3j3PNPHFB-m8omovQvBQ_u_2v0BAcf4Og
Cites_doi 10.1038/ncomms3019
10.1530/EC-18-0272
10.1111/j.1365-2826.2012.02383.x
10.3389/fimmu.2019.02349
10.1016/j.intimp.2018.01.048
10.1007/s00011-019-01222-2
10.4103/japtr.JAPTR_298_18
10.1016/j.jdiacomp.2016.10.017
10.3389/fneur.2017.00079
10.3390/medicina57121374
10.1530/EJE-22-0247
10.4103/ijem.IJEM_273_19
10.3389/fendo.2022.915394
10.1016/j.ejim.2016.03.028
10.2337/db11-0672
10.3389/fendo.2022.873699
10.1007/s12020-014-0502-9
10.1038/jhh.2012.52
10.1530/EJE-15-1061
10.1016/j.xcrm.2024.101629
10.1507/endocrj.EJ12-0427
10.3389/fendo.2023.1187725
10.1210/me.2010-0142
10.1074/jbc.C110.107375
10.1530/JOE-14-0440
10.2337/db07-1476
10.1186/1471-2458-7-220
10.1016/j.metabol.2009.07.003
10.1161/ATVBAHA.113.301599
10.15212/FMCH.2014.0118
10.1016/j.metabol.2021.154738
10.1210/en.2013-1902
10.3389/fpubh.2022.1020709
10.1210/jc.2015-1797
10.1210/er.2018-00163
10.1007/s12020-020-02484-1
10.1210/er.2008-0019
10.1080/0886022X.2023.2179336
10.1016/j.tem.2019.05.007
10.1111/j.1365-2265.2008.03502.x
10.1055/a-1778-4159
10.1373/clinchem.2010.155184
10.3389/fendo.2018.00800
10.1371/journal.pone.0129791
10.3390/biomedicines12061320
10.1186/1475-2840-12-124
10.1194/jlr.M051664
10.3390/cancers11081154
10.1172/JCI23606
10.21037/apm-21-525
10.2337/db18-1806-P
10.1007/s10753-017-0665-7
ContentType Journal Article
Copyright COPYRIGHT 2024 MDPI AG
2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2024 by the authors. 2024
Copyright_xml – notice: COPYRIGHT 2024 MDPI AG
– notice: 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2024 by the authors. 2024
DBID AAYXX
CITATION
NPM
7QR
8FD
8FE
8FH
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FR3
GNUQQ
HCIFZ
LK8
M7P
P64
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
7X8
5PM
ADTOC
UNPAY
DOA
DOI 10.3390/metabo14100565
DatabaseName CrossRef
PubMed
Chemoreception Abstracts
Technology Research Database
ProQuest SciTech Collection
ProQuest Natural Science Collection
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One
ProQuest Central Korea
Engineering Research Database
ProQuest Central Student
SciTech Premium Collection
Biological Sciences
Biological Science Database
Biotechnology and BioEngineering Abstracts
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
Unpaywall for CDI: Periodical Content
Unpaywall
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
ProQuest Central Student
Technology Research Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
Chemoreception Abstracts
ProQuest Central (New)
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
Biological Science Database
ProQuest SciTech Collection
Biotechnology and BioEngineering Abstracts
ProQuest One Academic UKI Edition
Engineering Research Database
ProQuest One Academic
ProQuest One Academic (New)
MEDLINE - Academic
DatabaseTitleList PubMed
MEDLINE - Academic

Publicly Available Content Database


CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: UNPAY
  name: Unpaywall
  url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/
  sourceTypes: Open Access Repository
– sequence: 4
  dbid: BENPR
  name: ProQuest Central Database Suite (ProQuest)
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Anatomy & Physiology
EISSN 2218-1989
ExternalDocumentID oai_doaj_org_article_8ecbed7c95b64e63ab09e87007eb0ac2
10.3390/metabo14100565
PMC11509456
A814401620
39452947
10_3390_metabo14100565
Genre Journal Article
GeographicLocations Hungary
United States--US
Germany
GeographicLocations_xml – name: Hungary
– name: United States--US
– name: Germany
GrantInformation_xml – fundername: National Research, Development and Innovation Office-NKFIH
  grantid: K142273 project
– fundername: National Research, Development and Innovation Office—NKFIH
  grantid: K142273 project
GroupedDBID 53G
5VS
8FE
8FH
AADQD
AAFWJ
AAYXX
AFKRA
AFPKN
AFZYC
ALMA_UNASSIGNED_HOLDINGS
BBNVY
BENPR
BHPHI
CCPQU
CITATION
DIK
GROUPED_DOAJ
HCIFZ
HYE
IAO
ITC
KQ8
LK8
M48
M7P
MODMG
M~E
OK1
PGMZT
PHGZM
PHGZT
PIMPY
PQGLB
PROAC
PUEGO
RPM
NPM
PMFND
7QR
8FD
ABUWG
AZQEC
DWQXO
FR3
GNUQQ
P64
PKEHL
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
ADRAZ
ADTOC
IPNFZ
RIG
UNPAY
ID FETCH-LOGICAL-c507t-96c04efb23af9c1a82e06a34b824c516b0c08b26f972207b71cab7a7c00badd83
IEDL.DBID M48
ISSN 2218-1989
IngestDate Wed Aug 27 01:31:58 EDT 2025
Sun Sep 07 11:12:18 EDT 2025
Tue Sep 30 17:07:27 EDT 2025
Fri Sep 05 00:05:23 EDT 2025
Fri Jul 25 12:02:15 EDT 2025
Tue Jun 17 22:04:33 EDT 2025
Tue Jun 10 21:08:49 EDT 2025
Mon Jul 21 06:05:39 EDT 2025
Wed Oct 01 01:14:51 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 10
Keywords fibroblast growth factor 21
hyperlipidemia
levothyroxine
thyroid
hypothyroidism
Hashimoto’s thyroiditis
FGF21
Language English
License https://creativecommons.org/licenses/by/4.0
Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
cc-by
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c507t-96c04efb23af9c1a82e06a34b824c516b0c08b26f972207b71cab7a7c00badd83
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0009-0000-5303-3082
0000-0002-9791-9288
0000-0002-9286-6471
0000-0003-0439-9867
0000-0001-9761-9595
0000-0002-4909-0065
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3390/metabo14100565
PMID 39452947
PQID 3120744677
PQPubID 2032362
ParticipantIDs doaj_primary_oai_doaj_org_article_8ecbed7c95b64e63ab09e87007eb0ac2
unpaywall_primary_10_3390_metabo14100565
pubmedcentral_primary_oai_pubmedcentral_nih_gov_11509456
proquest_miscellaneous_3120600632
proquest_journals_3120744677
gale_infotracmisc_A814401620
gale_infotracacademiconefile_A814401620
pubmed_primary_39452947
crossref_primary_10_3390_metabo14100565
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2024-10-01
PublicationDateYYYYMMDD 2024-10-01
PublicationDate_xml – month: 10
  year: 2024
  text: 2024-10-01
  day: 01
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
– name: Basel
PublicationTitle Metabolites
PublicationTitleAlternate Metabolites
PublicationYear 2024
Publisher MDPI AG
MDPI
Publisher_xml – name: MDPI AG
– name: MDPI
References ref_50
Biondi (ref_46) 2019; 40
Planavila (ref_8) 2013; 4
Bonde (ref_28) 2014; 55
Yu (ref_6) 2011; 57
Adams (ref_25) 2010; 285
Ates (ref_40) 2016; 174
Zhang (ref_26) 2015; 224
Semba (ref_21) 2013; 27
ref_19
Mraz (ref_16) 2009; 71
Gereben (ref_45) 2008; 29
Xiao (ref_29) 2015; 100
Salgado (ref_22) 2021; 118
Murphy (ref_23) 2013; 25
Lee (ref_32) 2013; 60
Tellechea (ref_43) 2021; 72
Kharitonenkov (ref_2) 2005; 115
Wang (ref_13) 2018; 41
ref_24
Fiorenza (ref_51) 2024; 5
Shen (ref_17) 2013; 12
Wang (ref_33) 2016; 31
Chow (ref_18) 2013; 33
Nason (ref_7) 2018; 67
Yong (ref_20) 2023; 45
Domouzoglou (ref_27) 2014; 155
ref_36
ref_35
Ueland (ref_48) 2022; 187
Stein (ref_15) 2010; 59
Bookout (ref_3) 2010; 24
ref_30
Mutsnaini (ref_11) 2019; 68
Lewis (ref_1) 2019; 30
ref_39
ref_38
ref_37
Jung (ref_10) 2017; 31
Bande (ref_31) 2019; 23
Tan (ref_5) 2011; 60
Ren (ref_52) 2021; 10
(ref_49) 2022; 54
Wang (ref_9) 2018; 56
ref_47
ref_44
Fu (ref_34) 2014; 2
Wang (ref_12) 2015; 49
Giannakou (ref_41) 2018; 7
Zhang (ref_14) 2008; 57
ref_4
Hussien (ref_42) 2018; 9
References_xml – volume: 4
  start-page: 2019
  year: 2013
  ident: ref_8
  article-title: Fibroblast growth factor 21 protects against cardiac hypertrophy in mice
  publication-title: Nat. Commun.
  doi: 10.1038/ncomms3019
– volume: 7
  start-page: 990
  year: 2018
  ident: ref_41
  article-title: The effect of obesity and dietary habits on oxidative stress in Hashimoto’s thyroiditis
  publication-title: Endocr. Connect.
  doi: 10.1530/EC-18-0272
– volume: 25
  start-page: 180
  year: 2013
  ident: ref_23
  article-title: Increased responses to the actions of fibroblast growth factor 21 on energy balance and body weight in a seasonal model of adiposity
  publication-title: J. Neuroendocrinol.
  doi: 10.1111/j.1365-2826.2012.02383.x
– ident: ref_35
  doi: 10.3389/fimmu.2019.02349
– volume: 56
  start-page: 301
  year: 2018
  ident: ref_9
  article-title: Improving hyperglycemic effect of FGF-21 is associated with alleviating inflammatory state in diabetes
  publication-title: Int. Immunopharmacol.
  doi: 10.1016/j.intimp.2018.01.048
– volume: 68
  start-page: 351
  year: 2019
  ident: ref_11
  article-title: Fibroblast growth factor 21 deficiency aggravates obesity-induced hypothalamic inflammation and impairs thermogenic response
  publication-title: Inflamm. Res.
  doi: 10.1007/s00011-019-01222-2
– volume: 9
  start-page: 113
  year: 2018
  ident: ref_42
  article-title: Levothyroxine improves Paraoxonase (PON-1) serum levels in patients with primary hypothyroidism: Case-control study
  publication-title: J. Adv. Pharm. Technol. Res.
  doi: 10.4103/japtr.JAPTR_298_18
– volume: 31
  start-page: 134
  year: 2017
  ident: ref_10
  article-title: The U-shaped relationship between fibroblast growth factor 21 and microvascular complication in type 2 diabetes mellitus
  publication-title: J. Diabetes Complicat.
  doi: 10.1016/j.jdiacomp.2016.10.017
– ident: ref_24
  doi: 10.3389/fneur.2017.00079
– ident: ref_37
  doi: 10.3390/medicina57121374
– volume: 187
  start-page: 293
  year: 2022
  ident: ref_48
  article-title: Novel inflammatory biomarkers in thyroid eye disease
  publication-title: Eur. J. Endocrinol.
  doi: 10.1530/EJE-22-0247
– volume: 23
  start-page: 557
  year: 2019
  ident: ref_31
  article-title: Serum Fibroblast Growth Factor 21 Levels in Patients with Hyperthyroidism and its Association with Body Fat Percentage
  publication-title: Indian J. Endocrinol. Metab.
  doi: 10.4103/ijem.IJEM_273_19
– ident: ref_38
  doi: 10.3389/fendo.2022.915394
– volume: 31
  start-page: 94
  year: 2016
  ident: ref_33
  article-title: Levothyroxine treatment restored the decreased circulating fibroblast growth factor 21 levels in patients with hypothyroidism
  publication-title: Eur. J. Intern. Med.
  doi: 10.1016/j.ejim.2016.03.028
– volume: 60
  start-page: 2758
  year: 2011
  ident: ref_5
  article-title: Fibroblast growth factor 21 (FGF21) in human cerebrospinal fluid: Relationship with plasma FGF21 and body adiposity
  publication-title: Diabetes
  doi: 10.2337/db11-0672
– ident: ref_4
  doi: 10.3389/fendo.2022.873699
– volume: 49
  start-page: 385
  year: 2015
  ident: ref_12
  article-title: A novel function for fibroblast growth factor 21: Stimulation of NADPH oxidase-dependent ROS generation
  publication-title: Endocrine
  doi: 10.1007/s12020-014-0502-9
– volume: 27
  start-page: 397
  year: 2013
  ident: ref_21
  article-title: Elevated serum fibroblast growth factor 21 is associated with hypertension in community-dwelling adults
  publication-title: J. Hum. Hypertens.
  doi: 10.1038/jhh.2012.52
– volume: 174
  start-page: 727
  year: 2016
  ident: ref_40
  article-title: The impact of levothyroxine sodium treatment on oxidative stress in Hashimoto’s thyroiditis
  publication-title: Eur. J. Endocrinol.
  doi: 10.1530/EJE-15-1061
– volume: 5
  start-page: 101629
  year: 2024
  ident: ref_51
  article-title: Weight-loss maintenance is accompanied by interconnected alterations in circulating FGF21-adiponectin-leptin and bioactive sphingolipids
  publication-title: Cell Rep. Med.
  doi: 10.1016/j.xcrm.2024.101629
– volume: 60
  start-page: 977
  year: 2013
  ident: ref_32
  article-title: Plasma FGF21 levels are increased in patients with hypothyroidism independently of lipid profile
  publication-title: Endocr. J.
  doi: 10.1507/endocrj.EJ12-0427
– ident: ref_44
  doi: 10.3389/fendo.2023.1187725
– volume: 24
  start-page: 2050
  year: 2010
  ident: ref_3
  article-title: Research resource: Comprehensive expression atlas of the fibroblast growth factor system in adult mouse
  publication-title: Mol. Endocrinol.
  doi: 10.1210/me.2010-0142
– volume: 285
  start-page: 14078
  year: 2010
  ident: ref_25
  article-title: Thyroid hormone regulates hepatic expression of fibroblast growth factor 21 in a PPARalpha-dependent manner
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.C110.107375
– volume: 224
  start-page: 289
  year: 2015
  ident: ref_26
  article-title: Thyroid hormone receptor regulates most genes independently of fibroblast growth factor 21 in liver
  publication-title: J. Endocrinol.
  doi: 10.1530/JOE-14-0440
– volume: 57
  start-page: 1246
  year: 2008
  ident: ref_14
  article-title: Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans
  publication-title: Diabetes
  doi: 10.2337/db07-1476
– ident: ref_39
  doi: 10.1186/1471-2458-7-220
– volume: 59
  start-page: 33
  year: 2010
  ident: ref_15
  article-title: Serum fibroblast growth factor 21 levels in gestational diabetes mellitus in relation to insulin resistance and dyslipidemia
  publication-title: Metabolism
  doi: 10.1016/j.metabol.2009.07.003
– volume: 33
  start-page: 2454
  year: 2013
  ident: ref_18
  article-title: Serum fibroblast growth factor-21 levels are associated with carotid atherosclerosis independent of established cardiovascular risk factors
  publication-title: Arter. Thromb. Vasc. Biol.
  doi: 10.1161/ATVBAHA.113.301599
– volume: 2
  start-page: 1
  year: 2014
  ident: ref_34
  article-title: Relationship between fibroblast growth factor 21 and thyroid stimulating hormone in healthy subjects without components of metabolic syndrome
  publication-title: Fam. Med. Community Health
  doi: 10.15212/FMCH.2014.0118
– volume: 118
  start-page: 154738
  year: 2021
  ident: ref_22
  article-title: FGF21 and Chronic Kidney Disease
  publication-title: Metabolism
  doi: 10.1016/j.metabol.2021.154738
– volume: 155
  start-page: 2031
  year: 2014
  ident: ref_27
  article-title: Fibroblast growth factor 21 and thyroid hormone show mutual regulatory dependency but have independent actions in vivo
  publication-title: Endocrinology
  doi: 10.1210/en.2013-1902
– ident: ref_36
  doi: 10.3389/fpubh.2022.1020709
– volume: 100
  start-page: 3800
  year: 2015
  ident: ref_29
  article-title: Elevated Serum Fibroblast Growth Factor 21 Levels in Patients with Hyperthyroidism
  publication-title: J. Clin. Endocrinol. Metab.
  doi: 10.1210/jc.2015-1797
– volume: 40
  start-page: 789
  year: 2019
  ident: ref_46
  article-title: Thyroid Dysfunction and Diabetes Mellitus: Two Closely Associated Disorders
  publication-title: Endocr. Rev.
  doi: 10.1210/er.2018-00163
– volume: 72
  start-page: 62
  year: 2021
  ident: ref_43
  article-title: Meta-analytic evidence for increased low-grade systemic inflammation and oxidative stress in hypothyroid patients. Can levothyroxine replacement therapy mitigate the burden?
  publication-title: Endocrine
  doi: 10.1007/s12020-020-02484-1
– volume: 29
  start-page: 898
  year: 2008
  ident: ref_45
  article-title: Cellular and molecular basis of deiodinase-regulated thyroid hormone signaling
  publication-title: Endocr. Rev.
  doi: 10.1210/er.2008-0019
– volume: 45
  start-page: 2179336
  year: 2023
  ident: ref_20
  article-title: Fibroblast growth factor 21 may be a strong biomarker for renal outcomes: A meta-analysis
  publication-title: Ren. Fail.
  doi: 10.1080/0886022X.2023.2179336
– volume: 30
  start-page: 491
  year: 2019
  ident: ref_1
  article-title: Going Back to the Biology of FGF21: New Insights
  publication-title: Trends Endocrinol. Metab.
  doi: 10.1016/j.tem.2019.05.007
– volume: 71
  start-page: 369
  year: 2009
  ident: ref_16
  article-title: Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity
  publication-title: Clin. Endocrinol.
  doi: 10.1111/j.1365-2265.2008.03502.x
– volume: 54
  start-page: 203
  year: 2022
  ident: ref_49
  article-title: FGF21: A Novel Regulator of Glucose and Lipid Metabolism and Whole-Body Energy Balance
  publication-title: Horm. Metab. Res.
  doi: 10.1055/a-1778-4159
– volume: 57
  start-page: 691
  year: 2011
  ident: ref_6
  article-title: Circadian rhythm of circulating fibroblast growth factor 21 is related to diurnal changes in fatty acids in humans
  publication-title: Clin. Chem.
  doi: 10.1373/clinchem.2010.155184
– ident: ref_30
  doi: 10.3389/fendo.2018.00800
– ident: ref_19
  doi: 10.1371/journal.pone.0129791
– ident: ref_50
  doi: 10.3390/biomedicines12061320
– volume: 12
  start-page: 124
  year: 2013
  ident: ref_17
  article-title: Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease
  publication-title: Cardiovasc. Diabetol.
  doi: 10.1186/1475-2840-12-124
– volume: 55
  start-page: 2408
  year: 2014
  ident: ref_28
  article-title: Thyroid hormone reduces PCSK9 and stimulates bile acid synthesis in humans
  publication-title: J. Lipid Res.
  doi: 10.1194/jlr.M051664
– ident: ref_47
  doi: 10.3390/cancers11081154
– volume: 115
  start-page: 1627
  year: 2005
  ident: ref_2
  article-title: FGF-21 as a novel metabolic regulator
  publication-title: J. Clin. Invest.
  doi: 10.1172/JCI23606
– volume: 10
  start-page: 3258
  year: 2021
  ident: ref_52
  article-title: Retrospective analysis of factors associated with serum levels of fibroblast growth factor-21 in patients with diabetes
  publication-title: Ann. Palliat. Med.
  doi: 10.21037/apm-21-525
– volume: 67
  start-page: 1806-P
  year: 2018
  ident: ref_7
  article-title: Glucagon Regulates Energy Balance via FGF-21 Signaling in the Brain
  publication-title: Diabetes
  doi: 10.2337/db18-1806-P
– volume: 41
  start-page: 73
  year: 2018
  ident: ref_13
  article-title: FGF-21 Plays a Crucial Role in the Glucose Uptake of Activated Monocytes
  publication-title: Inflammation
  doi: 10.1007/s10753-017-0665-7
SSID ssj0000605701
Score 2.2875435
Snippet Background/Objectives: Fibroblast growth factor 21 (FGF21) is a hormonal regulator of lipid and glucose metabolism exerting protection against atherosclerosis...
Fibroblast growth factor 21 (FGF21) is a hormonal regulator of lipid and glucose metabolism exerting protection against atherosclerosis by multiple actions on...
SourceID doaj
unpaywall
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 565
SubjectTerms Adipose tissue
Age
Arteriosclerosis
Atherosclerosis
Blood vessels
Body fat
C-reactive protein
Cardiovascular disease
Cholesterol
Diabetes
Enzyme-linked immunosorbent assay
FGF21
fibroblast growth factor 21
Fibroblast growth factors
Fibroblasts
Glucose
Glucose metabolism
Growth factors
Hashimoto’s thyroiditis
Health aspects
High density lipoprotein
Hormones
hyperlipidemia
Hypothalamus
Hypothyroidism
Kinases
levothyroxine
Lipid metabolism
Lipoproteins
Liver diseases
Measurement
Metabolic disorders
Obesity
Physiological aspects
Regression analysis
Statistical analysis
thyroid
Thyroid diseases
Thyroid gland
Thyroid hormones
Thyroiditis
Thyroxine
Triglycerides
Variables
Weight control
White people
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NjtMwELbQXuCCgOWny4IGCQGXaB3HcZJjQZSCFoTQrrS3yH9RK22TVZtq6Y3X4Myb8STMxGnVwGEvXGM7cWY-j7-JJzOMvYwzI9KkKiInkb5JJ3VkKpdEKkf6qgonTVcl4vMXNT2Xny7Si71SXxQTFtIDB8Gd5N4a7zJbpEZJrxJteOERZDzzhmvbWV_cxvacqWCDkYfwOGRpTNCvP1n4FqVKUY245aeDXahL1v-vSd7bk_6Ol7y9rq_05lpfXu5tRpN77G7PImEcZn-f3fL1A3Y4rtGDXmzgFXRxnd0H80P267S5BjQJ6wVM0DduDPLlFj6g-93OYNKV2wERwylFD4GuHXxsVzCmQ3Tv4FsoVY_KA7OBs9lm2cwdTJHoUo5_mNfwNSRmXQF90YUp1WZC7Te_f_xcbftT2iTAO-AjCBfL5jtSWyCT1cUp4M0fsvPJ-7N306gvzRBZJJBtVCjLpa-MSHRV2FjnwnOlE2lyIW0aK8Mtz41QVZEJwTOTxVabTGeWc4MWNU8esYMaJ_qEgUYHSCvrjEYmKmRuijzmVUGxXCledSP2equq8ipk4CjRcyGllkOljthb0uSuF2XO7i4gnsoeT-VNeMLHEQ5KWt-obKv73xRwspQpqxzndBweK8FH7HjQE9elHTZvkVT2dmFVJjFKAz3wLBuxF7tmGkmxbrVv1qGPIuqIc3kcgLd7paSgg3KJo_MBJAfvPGyp57MuazhRfxytRuzNDr03CPTofwj0KbsjkAiGAMhjdtAu1_4ZErnWPO_W7B-8VkvV
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Lb9QwELbK9gAXBJRHoCAjIeAS1XEcJzkgtEVdFlRWVdVKvUV-hV2pmyy7WZW98Tc488_4JczksTQgwTW2E9szHn9jT74h5EUQax6FeepbAfBNWKF8ndvQlwnAV5laoessEZ8mcnwuPl5EFztk0v0Lg2GVnU2sDbUtDZ6RH4QBh90OlnX8dvHFx6xReLvapdBQbWoF-6amGLtBdtEkiwHZPTyanJxuT10YoPeYBQ17Ywj-_sHcVTDbGO0IUCDq7U41if_fpvraXvVnHOXNdbFQmyt1eXltkxrdIbdbdEmHjTrcJTuuuEf2hgV41vMNfUnreM_6IH2P_DguryiYivWcjsBnLjXg6Iq-B7e8mtJRnYaH8oAeY1QRVYWlH6oVHeLlurP0tElhD0KlekPPpptlObN0DAAYuf_prKAnDWHriuJJLx1jzibQivLnt--rrj7SKVF4A3wC9WVZfgXIS9GU1fEL8PL75Hx0dPZu7LcpG3wDwLLyU2mYcLnmocpTE6iEOyZVKHTChYkCqZlhieYyT2MO8tRxYJSOVWwY02Bpk_ABGRTQ0UeEKnCMlDRWK0CoXCQ6TQKWpxjjFcFT65FXnaiyRcPMkYFHg0LN-kL1yCFKclsLGbXrB-Xyc9Yu0CxxRjsbmzTSUjgZKs1SB8aMxU4zZTh8DvUgw3UPwjaq_X0BOosMWtkwwWvyQHLmkf1eTVivpl_caVLW2otV9lu7PfJ8W4wtMQaucOW6qSMRUkJfHjaKtx1SmOIFuoDWSU8le2PulxSzac0mji4BtJYeeb3V3v9M6ON_D-EJucUB-jUhj_tkUC3X7ilAt0o_a9fjL_vESKs
  priority: 102
  providerName: ProQuest
– databaseName: Unpaywall
  dbid: UNPAY
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1fb9MwELege4AXBow_HQMdEgJesjmO4ySPAdEVNKYJrdJ4imzHUSvWdFpTTeWJr8Ez34xPwl2SVs1AGq_xObHP57vf2Zc7xl75kRFhUCReLhG-yVxqzxR54KkY4atKcmnqKhGfj9VwJD-dhWdtgCz9C7Nxfx-gO34wdRUyg4IR0VKHt9mWCtFL7rGt0fFJ-pUqx6GN8ijwp8nI-I9OHYtTJ-b_W_1u2J_rsZF3FuWFXl7p8_MNwzPYZoerITfxJt_2F5XZt9-vZXO8eU732b0We0LaCMsDdsuVD9lOWqLfPV3Ca6ijQetj9h3262h2BahIFlMYoEc9M4iyKzhEp70aw6Au0gPChyOKOQJd5vCxmkNKV-8uhy9NgXtccjBLOB0vL2eTHIYIj6kyAExKOGnSuc6BzoFhSBWdUGZmv3_8nK_oKdkS4BvwEyRNOH0ExECKro5uwJc_YqPBh9P3Q68t6OBZhJ2VlyjLpSuMCHSRWF_HwnGlA2liIW3oK8Mtj41QRRIJwSMT-VabSEeWc4N6OA4es16JA33KQKPbpJXNjUb8KmRsktjnRUKCEOLTvM_erBY9u2jydmTo7xD_sy7_--wdycSaivJt1w9wybJ2-2axs8blkU1Co6RTgTY8cajqeOQM11bg50iiMtIKKDZWtz834GApv1aWxnSJ7ivB-2yvQ4m72XabVzKZtdpkngU-cgP99ijqs5frZupJEXKlmy0aGkWAE8fypBHh9ZSChK7XJfaOO8LdmXO3pZyM61zj5DBgb9Vnb9f74AaG7v4_6TN2VyBIbIIj91ivuly45wjyKvOi3eF_AHZWUxQ
  priority: 102
  providerName: Unpaywall
Title Low Serum Fibroblast Growth Factor 21 Level and Its Altered Regulation by Thyroid Hormones in Patients with Hashimoto’s Thyroiditis on Levothyroxine Substitution
URI https://www.ncbi.nlm.nih.gov/pubmed/39452947
https://www.proquest.com/docview/3120744677
https://www.proquest.com/docview/3120600632
https://pubmed.ncbi.nlm.nih.gov/PMC11509456
https://doi.org/10.3390/metabo14100565
https://doaj.org/article/8ecbed7c95b64e63ab09e87007eb0ac2
UnpaywallVersion publishedVersion
Volume 14
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAFT
  databaseName: Colorado Digital library
  customDbUrl:
  eissn: 2218-1989
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000605701
  issn: 2218-1989
  databaseCode: KQ8
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 2218-1989
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000605701
  issn: 2218-1989
  databaseCode: DOA
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 2218-1989
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000605701
  issn: 2218-1989
  databaseCode: DIK
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 2218-1989
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000605701
  issn: 2218-1989
  databaseCode: M~E
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVAQN
  databaseName: PubMed Central
  customDbUrl:
  eissn: 2218-1989
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000605701
  issn: 2218-1989
  databaseCode: RPM
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
– providerCode: PRVPQU
  databaseName: ProQuest Central Database Suite (ProQuest)
  customDbUrl: http://www.proquest.com/pqcentral?accountid=15518
  eissn: 2218-1989
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000605701
  issn: 2218-1989
  databaseCode: BENPR
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVFZP
  databaseName: Scholars Portal Journals: Open Access
  customDbUrl:
  eissn: 2218-1989
  dateEnd: 20250831
  omitProxy: true
  ssIdentifier: ssj0000605701
  issn: 2218-1989
  databaseCode: M48
  dateStart: 20111101
  isFulltext: true
  titleUrlDefault: http://journals.scholarsportal.info
  providerName: Scholars Portal
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1fb9MwELfG9gAvCBiwwqgOCQ1eAo6TOMkDQh1aKWirpmmVxlNkOy6t1CZdm2rrG1-DZ74Zn4S7JK0WmODV_2L7zne_sy93jL1yQy0Cbxg7qY_wzU995ehh6jkyQvgq49TXZZaIk77sDfwvF8HFFlu78tYbuLjVtKN8UoP55O315eoDHvj3ZHGiyf5uagvcMHJYRG0eHMwuHUoqRY-vdYaNO2wHFZVLofVPavRfCWoEK9ytQjneMlJDVZUR_f-W2zcU159OlXeX2UytrtRkckNjdR-w-zXUhE7FGw_Zls0esd1Ohmb2dAUHUDp_lrfqu-zncX4FKDeWU-iiAZ1rBNUFfEIbvRhBt8zJA8KFY3IxApWl8LlYQIde2m0KZ1U-e6Qw6BWcj1bzfJxCD9EwJQKAcQanVfTWBdC1L_QogROySP7r-4_Fuj3FVgIcAT9BzDPPrxH_Asm10pkBB3_MBt2j8489p87f4BhEmYUTS8N9O9TCU8PYuCoSlkvl-ToSvglcqbnhkRZyGIdC8FCHrlE6VKHhXKPYjbwnbDvDie4xUGglKWlSrRCuCj_SceTyYUwOXwGWpi32ek2qZFaF6UjQvCGiJk2ittghUXLTisJrlwX5_FtSn9YkskbbNDRxoKVvpac0jy1KNh5azZUR-Dnig4TYEoltVP0vA06WwmklnYjezF0peIvtN1ri4TXN6jUnJWveTzwXdwPN9DBssZebaupJDnGZzZdVG0n4EufytGK8zZK8mF7TfewdNViyseZmTTYelaHFyT7A3rLF3my49z8b-uzfS3jO7gnEgZX_4z7bLuZL-wJxXKHbbOfwqH961i7vQdrl2cSyQf-08_U3MEZRTw
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF6V9FAuCCiPQIFF4nWxul7ba_tQoRQaEppGVdVKvZnd9bqJ1NghcRRy429w5n_wY_glzPgRapDg1Kv34V3P-NtvdmdnCHlh-4p7ThJasQv0zY1daakkdiwRAH0VYeyqIkvE0VD0ztyP5975BvlR34VBt8oaEwugjjONe-S7js1htYPf2n87_Wxh1ig8Xa1TaMgqtUK8V4QYqy52HJrVEky4-V7_Pcj7Jefdg9N3PavKMmBp4EK5FQrNXJMo7sgk1LYMuGFCOq4KuKs9WyimWaC4SEKfwxCUb2upfOlrxhSAQ-BAvzfIJtAO7rbI5v7B8PhkvcvDwFrwmV1Gi3SckO1OTA7SRe9KoB5eYzUskgb8vTRcWRv_9NvcWqRTuVrKy8sri2L3NrlVsVnaKdXvDtkw6V2y3UnBkp-s6Cta-JcWG_fb5PsgW1KApsWEdsFGzxTw9px-mGXLfES7Rdofym06QC8mKtOY9vM57eBhvonpibmo8oxRtaKno9UsG8e0B4Qbcw3QcUqPywCxc4o7y7SHOaJAC7OfX7_N6_oYvolCD_AK1M9Z9gUoNkXoLPwloPN75OxahHeftFIY6ENCJRhiUuhYSWDE3A1UGNgsCdGnzIOncZu8rkUVTctIIBFYUCjUqCnUNtlHSa5rYQTv4kE2u4gqQIgCo5WJfR16SrhGOFKx0AB4Mt8oJjWH16EeRIgzIGwtq-sSMFiM2BV1AjyWtwVnbbLTqAn4oJvFtSZFFT7No99_U5s8XxdjS_S5S022KOsIpLAwlgel4q2n5IR4YO9C66Chko05N0vS8aiIXo4mCLQWbfJmrb3_-aCP_j2FZ2Srd3o0iAb94eFjcpMD7SzdLXdIK58tzBOgjbl6Wv2blHy6bjj4BYrkhdw
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtNAEF6VVAIuCCg_gQKLxN_Fynptr-1DhVLakNAQRVUr9WZ21-smUmOHxFHIjdfgzNvwGDwJM7YTapDg1Kv3x7ue8bff7M7OEPLC9hX3nCS0Yhfomxu70lJJ7FgiAPoqwthVRZaIjwPRPXU_nHlnW-TH-i4MulWuMbEA6jjTuEfecmwOqx381n4rqdwihgedt9PPFmaQwpPWdToNWaVZiPeKcGPVJY8js1qCOTff6x2A7F9y3jk8ede1qowDlgZelFuh0Mw1ieKOTEJty4AbJqTjqoC72rOFYpoFiosk9DkMR_m2lsqXvmZMAVAEDvR7jWz7ThiwBtnePxwMjzc7PgwsB5_ZZeRIxwlZa2JykDR6WgIN8WorY5FA4O9l4tI6-acP541FOpWrpby4uLRAdm6TWxWzpe1SFe-QLZPeJTvtFKz6yYq-ooWvabGJv0O-97MlBZhaTGgH7PVMAYfP6ftZtsxHtFOkAKLcpn30aKIyjWkvn9M2HuybmB6b8yrnGFUrejJazbJxTLtAvjHvAB2ndFgGi51T3GWmXcwXBRqZ_fz6bb6uj6GcKPQAr0BdnWVfgG5ThNHCdwI6v0dOr0R490kjhYE-JFSCUSaFjpUEdszdQIWBzZIQ_cs8eBo3yeu1qKJpGRUkAmsKhRrVhdok-yjJTS2M5l08yGbnUQUOUWC0MrGvQ08J1whHKhYaAFLmG8Wk5vA61IMIMQeErWV1dQIGi9G7onaAR_S24KxJdms1ASt0vXitSVGFVfPo95_VJM83xdgS_e9Sky3KOgLpLIzlQal4myk5IR7eu9A6qKlkbc71knQ8KiKZozkCrUWTvNlo738-6KN_T-EZuQ6wEPV7g6PH5CYHBlp6Xu6SRj5bmCfAIHP1tPo1Kfl01WjwC5c4ihY
linkToUnpaywall http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1fb9MwELege4AXBow_HQMdEgJesjmO4ySPAdEVNKYJrdJ4imzHUSvWdFpTTeWJr8Ez34xPwl2SVs1AGq_xObHP57vf2Zc7xl75kRFhUCReLhG-yVxqzxR54KkY4atKcmnqKhGfj9VwJD-dhWdtgCz9C7Nxfx-gO34wdRUyg4IR0VKHt9mWCtFL7rGt0fFJ-pUqx6GN8ijwp8nI-I9OHYtTJ-b_W_1u2J_rsZF3FuWFXl7p8_MNwzPYZoerITfxJt_2F5XZt9-vZXO8eU732b0We0LaCMsDdsuVD9lOWqLfPV3Ca6ijQetj9h3262h2BahIFlMYoEc9M4iyKzhEp70aw6Au0gPChyOKOQJd5vCxmkNKV-8uhy9NgXtccjBLOB0vL2eTHIYIj6kyAExKOGnSuc6BzoFhSBWdUGZmv3_8nK_oKdkS4BvwEyRNOH0ExECKro5uwJc_YqPBh9P3Q68t6OBZhJ2VlyjLpSuMCHSRWF_HwnGlA2liIW3oK8Mtj41QRRIJwSMT-VabSEeWc4N6OA4es16JA33KQKPbpJXNjUb8KmRsktjnRUKCEOLTvM_erBY9u2jydmTo7xD_sy7_--wdycSaivJt1w9wybJ2-2axs8blkU1Co6RTgTY8cajqeOQM11bg50iiMtIKKDZWtz834GApv1aWxnSJ7ivB-2yvQ4m72XabVzKZtdpkngU-cgP99ijqs5frZupJEXKlmy0aGkWAE8fypBHh9ZSChK7XJfaOO8LdmXO3pZyM61zj5DBgb9Vnb9f74AaG7v4_6TN2VyBIbIIj91ivuly45wjyKvOi3eF_AHZWUxQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Low+Serum+Fibroblast+Growth+Factor+21+Level+and+Its+Altered+Regulation+by+Thyroid+Hormones+in+Patients+with+Hashimoto%E2%80%99s+Thyroiditis+on+Levothyroxine+Substitution&rft.jtitle=Metabolites&rft.au=Berta%2C+Eszter&rft.au=Halmi%2C+S%C3%A1ndor&rft.au=Moln%C3%A1r%2C+Istv%C3%A1n&rft.au=Hutkai%2C+D%C3%A1vid&rft.date=2024-10-01&rft.pub=MDPI+AG&rft.eissn=2218-1989&rft.volume=14&rft.issue=10&rft.spage=565&rft_id=info:doi/10.3390%2Fmetabo14100565&rft.externalDBID=HAS_PDF_LINK
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2218-1989&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2218-1989&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2218-1989&client=summon